TerminatedPhase 2NCT04083170

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fred Hutchinson Cancer Center
Principal Investigator: Filippo Milano, M.D
Fred Hutch/University of Washington Cancer Consortium
Intervention: Fludarabine(drug)
Enrollment: 1 enrolled
Eligibility: 65 years · All sexes
Timeline: 2022 – 2022

Study locations (5)

University of California San Francisco, San Francisco, California, United States
Children's National Medical Center, Washington D.C., District of Columbia, United States
Case Western Reserve University, Cleveland, Ohio, United States
Cleveland Cord Blood Center, Cleveland, Ohio, United States
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04083170 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials